Divis Laboratories Ltd Share Price Today - Divis Laboratories Ltd Stock Price Live NSE/BSE

Divis Laboratories Ltd

NSE: DIVISLAB BSE: 532488

₹5952.50

(-1.71)%

Mon, 02 Feb 2026, 09:25 pm

MTF 5xInvest in Divis Laboratories Ltd with 5x Leverage Buy with MTF

Market Cap1607.21B

PE Ratio63.59

Dividend0.50

Health Technology

Pharmaceuticals: Major

24.5K

1 Day

0 (0%)

No Result Found

Summary

Market Cap
160401.43
Net Profit
2191
P/B
10.22
Sector P/E
31.71
P/E
69.82
EV/EBITDA
44.95
Debt/Equity (Industry)
0.16
Interest Cover (Industry)
22.44
ROCE (Industry)
20.01
RONW (Industry)
16.77
ROE
15.35
ROCE
20.42
Debt/Equity
0
EPS (TTM)
93.61
Dividend Yield
0.50
Book Value
580.60
Interest Cover
973

Analysis

all

Pros

Dividends per share have increased over the past 10 years.
Dividends paid are well covered by earnings (3.2x coverage).
Dividends after 3 years are expected to be well covered by earnings (3.1x coverage).
Dividends per share have been stable in the past 10 years.
Divi's Laboratories's earnings growth is expected to exceed the India market average.

Cons

Divi's Laboratories's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
Divi's Laboratories's dividend is below the markets top 25% of dividend payers in India (3.08%).
Cash flow for Divi's Laboratories is expected to increase but not above the 50% threshold in 2 years time.
Divi's Laboratories's earnings are expected to grow by 18.9% yearly, however this is not considered high growth (20% yearly).
Divi's Laboratories's net income is expected to increase but not above the 50% threshold in 2 years time.

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	51.88	51.89	51.89	51.89	51.89
FII	20.08	19.39	19.74	18.01	17.99
DII	19.28	19.76	19.05	20.71	20.54
Public	8.76	8.96	9.32	9.39	9.58
Government	0.00	0.00	0.00	0.00	0.00

Technical Analysis

RSI

34.69

MACD

-111.44

50 DMA

6344.56

200 DMA

6369.13

Support and Resistance

Type	R1	R2	R3	PP	S1	S2	S3
Classic	7798.83	7022.33	6536.67	6245.83	5760.17	5469.33	4692.83
Fibonacci	7022.33	6725.71	6542.46	6245.83	5949.21	5765.96	5469.33
Camarilla	6264.54	6193.36	6122.18	6245.83	5979.82	5908.64	5837.46

Pivots Level: Classic

+1553

7798.83

+776.50

7022.33

+290.83

6536.67

6245.83

Pivot Point

LTP: 5952.50

-485.67

5760.17

-776.50

5469.33

-1553

4692.83

Moving Average

SMAEMA

Period

Value

10-EMA
6084.28
20-EMA
6178.85
30-EMA
6237.84
50-EMA
6296.63
100-EMA
6326.72
200-EMA
6230.66

Announcement Date	Purpose	Action	Ex Date
07 Nov 2025	board-meetings	Quarterly Results
17 May 2025	agm
17 May 2025	dividend	₹30.00 Dividend /Share	25 Jul 2025
25 May 2024	dividend	₹30.00 Dividend /Share	02 Aug 2024
25 May 2024	agm
03 Jul 2023	agm
20 May 2023	dividend	₹30.00 Dividend /Share	11 Aug 2023
04 Jul 2022	agm
23 May 2022	dividend	₹30.00 Dividend /Share	12 Aug 2022
19 Jul 2021	agm

Divis Laboratories Ltd

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd

Cipla Ltd

Lupin Ltd

About Divis Laboratories Ltd

Divis Laboratories is engaged in the manufacture of Active Pharmaceutical ingredients (API’s), Intermediates and Nutraceutical ingredients with predominance in exports.

Industry

Pharmaceuticals - Indian - Bulk Drugs

Founded

1990

Headquarters

CEO

Ramesh B V Nimmagadda

Employees

Contact

Website

http://www.divislabs.com

mail@divislaboratories.com; cs@divislaboratories.c

Phone

91-40-23786300/23786352/400

Location

1-72-23(P)/DIVIS/303 Divi Towe, Cyber Hills Gachibowli, Hyderabad, Telangana, 500032

Year	History
2019	Divi's Laboratories approved an additional investment of $250M towards expansion of production blocks in Unit-I and Unit-II. The 7th USFDA inspection in Unit 2 took place.
2020	Commissioning of new production blocks in DC SEZ at Unit-I and DCV SEZ at Unit-II occurred. US-FDA inspection of Unit-II at Village Chippada, Andhra Pradesh took place. Commencement of commercial production from DCV-SEZ Unit began. Construction of Divi's Laboratories Unit-III Facility near Kakinada commenced.
2021	Ground breaking of the manufacturing plant in Kakinada took place.
2022	Divi's Laboratories received the EHS excellence Award. Divi's Laboratories reached the milestone of being one among the top 3 API manufacturers in the world and one among the top API companies in Hyderabad.
2024	Divi's Laboratories has a global presence in supplying APIs to more than 100 countries.

Client Name	Order Side	QTY	Avg Price	Date
No Result Found

divis laboratories ltd. News

Divi's Labs Board Meet on Feb 11 for Q3FY26 Results

Divi's Laboratories has scheduled a board meeting on February 11, 2026, to consider and approve Q3FY26 financial results. Trading window remains closed until February 13, 2026.

30 Jan 2026

co actions results

Divis Labs Dec Exports Surge 49% MoM to $117m

Divis Laboratories reported strong December export performance with $117 million in shipments, marking a significant 49% month-on-month growth and demonstrating robust international demand.

13 Jan 2026

stocks

Divi's Labs Sees ₹66.53 Cr NSE Block Trade

Divi's Laboratories witnessed a significant block trade on NSE worth ₹66.53 crores involving 103,549 shares at ₹6,424.50 per share, indicating substantial institutional activity in the pharmaceutical stock.

12 Jan 2026

co actions results

Morgan Stanley Sets Overweight Rating on Divi's Labs

Morgan Stanley maintains overweight rating on Divi's Laboratories with price target of ₹7,541.00, reflecting positive outlook on the pharmaceutical company's prospects.

22 Dec 2025

stocks

Divi's Labs Reports Strong Export Growth in December

Divi's Laboratories achieved remarkable 68% month-over-month and 17% year-over-year export growth in US dollar terms, demonstrating strong international market performance.

19 Dec 2025

co actions results

Showing 1–5 of 53

Rows per page:

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800